Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $27.5 million.

  • Stoke Therapeutics' Share-based Compensation rose 7.27% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.6 million, marking a year-over-year increase of 11.83%. This contributed to the annual value of $27.5 million for FY2024, which is 8.70% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Share-based Compensation of $27.5 million as of FY2024, which was up 8.70% from $25.3 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Share-based Compensation peaked at $27.5 million during FY2024, and registered a low of $5.8 million during FY2020.
  • Over the past 3 years, Stoke Therapeutics' median Share-based Compensation value was $25.3 million (recorded in 2023), while the average stood at $25.2 million.
  • Data for Stoke Therapeutics' Share-based Compensation shows a peak YoY skyrocketed of 201.77% (in 2020) over the last 5 years.
  • Over the past 5 years, Stoke Therapeutics' Share-based Compensation (Yearly) stood at $5.8 million in 2020, then surged by 184.48% to $16.5 million in 2021, then spiked by 38.79% to $22.9 million in 2022, then climbed by 10.48% to $25.3 million in 2023, then grew by 8.70% to $27.5 million in 2024.